menu
    • menu
    [{"orgOrder":0,"company":"Maruishi Pharmaceutical","sponsor":"CARA Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Maruishi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Maruishi Pharmaceutical \/ Maruishi Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Maruishi Pharmaceutical \/ Maruishi Pharmaceutical"},{"orgOrder":0,"company":"Maruishi Pharmaceutical","sponsor":"Allay Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Bupivacaine","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Maruishi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Maruishi Pharmaceutical \/ Maruishi Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Maruishi Pharmaceutical \/ Maruishi Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Maruishi Pharmaceutical

    Menu

    Maruishi Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Maruishi Pharmaceutical

                            Japan arrow
                            CPhI India 2024
                            Not Confirmed

                            Maruishi Pharmaceutical

                            Japan arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bupivacaine

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase II

                            Recipient : Allay Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Allay Therapeutics Announces Development and Commercialization Agreement with Maruishi Pharmaceutical for Ultr...

                            Details : Under the agreement, Maruishi will have the exclusive rights to develop and commercialize Allay’s lead investigational drug candidate, ATX101, a non-opioid, bupivacaine-based drug product, and other ultra-sustained analgesic implantable drug candidates...

                            Brand Name : ATX-101

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 18, 2023

                            Lead Product(s) : Bupivacaine

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase II

                            Recipient : Allay Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Maruishi Pharmaceutical

                            Japan arrow
                            CPhI India 2024
                            Not Confirmed

                            Maruishi Pharmaceutical

                            Japan arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Difelikefalin

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Recipient : CARA Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus ...

                            Details : Korsuva (difelikefalin) injection is a kappa opioid receptor agonist indicated for the treatment of moderate-to-severe pruritus in hemodialysis patients.

                            Brand Name : Korsuva

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            September 25, 2023

                            Lead Product(s) : Difelikefalin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Recipient : CARA Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth